BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

July 16, 2012 7:00 AM UTC

BioMimetic Therapeutics Inc. (NASDAQ:BMTI) gained $0.66 (24%) to $3.46 on Tuesday after submitting to FDA an amendment to the PMA for Augment Bone Graft, which is under review for use as an alternative to autograft in hindfoot and ankle fusion procedures. The amendment contains data showing the primary endpoint in company's Phase III trial is reproducible based on new blinded inter-observer assessments of the scans. In January, the agency asked for additional information despite an advisory panel's positive vote last year on the product.

BioMimetic said it continues to expect a final decision from FDA between April 2013 and January 2014. Its shares gained $0.67 (24%) to $3.50 on the week...